Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Public ClinicalTrials.gov record NCT00690430. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-related Symptoms Are Inadequately Controlled by Somatostatin Analogues.
Study identification
- NCT ID
- NCT00690430
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 186 participants
Conditions and interventions
Interventions
- Octreotide Drug
- Pasireotide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2008
- Primary completion
- Mar 31, 2012
- Completion
- Mar 31, 2012
- Last update posted
- Jul 29, 2013
2008 – 2012
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service | Scottsdale | Arizona | 85258 | — |
| University of Arizona / Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Loma Linda University Dept. of Loma Linda CancerCent | Loma Linda | California | 92354 | — |
| Cedars Sinai Medical Center Cedars Sinai 4 | Los Angeles | California | 90048 | — |
| H. Lee Moffitt Cancer Center/University of South Florida Dept of H. Lee Moffit | Tampa | Florida | 33612 | — |
| Mount Sinai School of Medicine Study Coordinator | New York | New York | 10029 | — |
| Montefiore Medical Center MMC | The Bronx | New York | 10467 | — |
| Duke University Medical Center Dept. of Duke Cancer Center(2) | Durham | North Carolina | 27710 | — |
| St. Luke's Hospital and Health Network St. Luke's Cancer Network | Bethlehem | Pennsylvania | — | — |
| MD Anderson Cancer Center/University of Texas Dept. of MD Anderson (9) | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00690430, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2013 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00690430 live on ClinicalTrials.gov.